Ironwood Pharmaceuticals (IRWD) Share-based Compensation (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Share-based Compensation across 17 years of filings, most recently posting $3.7 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $3.7 million, down 30.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.6 million (down 41.65% YoY), and the FY2025 annual result was $17.2 million, down 42.21% from the prior year.
• Share-based Compensation came in at $3.7 million for Q1 2026 at Ironwood Pharmaceuticals, down from $3.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $8.7 million in Q4 2023 to a low of $3.6 million in Q3 2025.
• The 5-year median for Share-based Compensation is $7.1 million (2022), against an average of $6.5 million.
• Across the five-year window, Share-based Compensation jumped 43.84% in 2022 and tumbled 56.63% in 2025, its largest moves.
• Ironwood Pharmaceuticals' Share-based Compensation stood at $7.3 million in 2022, then advanced by 19.38% to $8.7 million in 2023, then sank by 47.54% to $4.6 million in 2024, then declined by 16.27% to $3.8 million in 2025, then slipped by 4.45% to $3.7 million in 2026.
• The last three Share-based Compensation figures came in at $3.7 million (Q1 2026), $3.8 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.